An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

Katherine E. Olson, Mai M. Abdelmoaty, Krista L. Namminga, Yaman Lu, Helen Obaro, Pamela Santamaria, R. Lee Mosley, Howard E. Gendelman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers'. Together they form a unique fingerprint.

Medicine & Life Sciences